NOSIUM (NOSIUM ) Q2 2025 earnings summary

Executive summary

• Revenue declined significantly both at the parent and group level, with a 70% drop for the parent and 34% for the group compared to Q2 2024.

• Operating losses narrowed year-over-year due to substantial cost reductions.

• Strategic divestment of Framgångsgården AB for 5.6 MSEK completed, strengthening capital structure.

• Letter of intent signed for a potential reverse acquisition with Medicortex Finland Oyj, which could lead to a business transformation.

Financial highlights

• Q2 2025 group revenue: 1,433 TKR (down 34% YoY); operating result: -1,013 TKR (improved from -2,063 TKR YoY).

• Q2 2025 parent revenue: 60 TKR (down 70% YoY); operating result: -583 TKR (improved from -897 TKR YoY).

• Group net result attributable to shareholders: -961 TKR (improved from -2,870 TKR YoY).

• Cash flow from operations improved to -901 TKR (from -3,875 TKR YoY) at group level.

• Group equity at period end: 25,615 TKR (down from 52,865 TKR YoY).

Outlook and guidance

• Ongoing focus on strategic transactions and selective investments with high value potential.

• Actively seeking buyers for remaining holdings in line with the new strategic direction.

• Anticipates further updates on the Medicortex transaction in the coming months.